In clinical trials, nausea (12-22%), diarrhea (12-16%), vomiting (5-9%), constipation (6-7%), abdominal pain (6-9%), and dyspepsia (7-10%) were frequently reported
diyabet tedavisi iin gelitirilmitir
The most important caveat: if youre on a GLP-1 medication and considering adding NAD+ supplementation, talk with your clinician first
While tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing and cardiovascular benefits are not yet established, the medication has shown favorable effects on multiple cardiometabolic risk factors
The Signature Skinny Shot by LJCSC features medically monitored semaglutide (GLP-1) and tirzepatide (GLP-1 and GIP) injections, along with recommended appetite-suppressing supplements, to help you achieve your weight-loss goals